Canada Spends Logo

Explore our Budget 2026 analysis

Grant: New Investigator Award-PA:Ontario HIV Treatment Network-Biomed/Clinical Research

Unity Health Toronto

$0.00

A Clinical Trials Research Program in Biomedical HIV Prevention and HIV/STI Co-infections

FY 2013-14

Summary
Despite decades of traditional prevention efforts, Canada continues to see unacceptably high rates of HIV and sexually transmitted infections (STIs) such as syphilis and herpes simplex virus type 2 (HSV-2), with a disproportionate burden among men who have sex with men (MSM). As an infectious diseases specialist physician and clinical epidemiologist, my research program focuses on clinical trials of novel strategies for the prevention, detection and management of HIV and STI co-infections. First, I lead an interdisciplinary team investigating a safe, effective new approach to HIV prevention known as pre-exposure prophylaxis (PrEP). PrEP involves daily use of anti-HIV medications by people at high, ongoing risk of HIV, but there are concerns about its acceptability, the ability of users to adhere, and other clinical issues. I am launching a pilot PrEP trial among high risk Toronto MSM that will gather preliminary data on these issues and inform the design of a future nationwide trial. My related studies in this area address other ways to optimize the clinical and public health impact of PrEP in the future. Second, given the exceedingly high burden of syphilis in HIV-infected MSM and the many negative interactions between these pathogens, I am co-leading a clinical trial of new approaches to diagnosing syphilis in HIV-infected MSM that will inform future strategies for controlling these STIs. Third, I am co-leading an international randomized controlled trial in the area of HIV and HSV-2 co-infection, studying whether the anti-herpes medication valacyclovir can slow the rate at which HIV disease progresses. Although there are several potentially harmful ways in which HIV and herpes interact with each other, valacyclovir and related anti-herpes medications are safe and inexpensive. The rationale underlying this trial and my other studies in this area is that these medications could therefore be exploited for clinical benefit by reversing these harmful effects.
Program
New Investigator Award-PA:Ontario HIV Treatment Network-Biomed/Clinical Research
Location
Ontario, Canada
Recipient Type
Other
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
307944
Name
Tan Darrell H
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Ontario HIV Treatment Network
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Health Professional Awards - New Investigators
Projecttitle
A Clinical Trials Research Program in Biomedical HIV Prevention and HIV/STI Co-infections
Programtype2
Salary Programs
Orgnameinp2
Unity Health Toronto
Cihramount2
$0
Cihrequipment2
$0
Programname2
New Investigator Award-PA:Ontario HIV Treatment Network-Biomed/Clinical Research
Keyworddelim
Clinical Trials; Herpes Simplex Virus; Hiv; Prevention; Sexually Transmitted Infections; Syphilis
Abstract
Despite decades of traditional prevention efforts, Canada continues to see unacceptably high rates of HIV and sexually transmitted infections (STIs) such as syphilis and herpes simplex virus type 2 (HSV-2), with a disproportionate burden among men who have sex with men (MSM). As an infectious diseases specialist physician and clinical epidemiologist, my research program focuses on clinical trials of novel strategies for the prevention, detection and management of HIV and STI co-infections. First, I lead an interdisciplinary team investigating a safe, effective new approach to HIV prevention known as pre-exposure prophylaxis (PrEP). PrEP involves daily use of anti-HIV medications by people at high, ongoing risk of HIV, but there are concerns about its acceptability, the ability of users to adhere, and other clinical issues. I am launching a pilot PrEP trial among high risk Toronto MSM that will gather preliminary data on these issues and inform the design of a future nationwide trial. My related studies in this area address other ways to optimize the clinical and public health impact of PrEP in the future. Second, given the exceedingly high burden of syphilis in HIV-infected MSM and the many negative interactions between these pathogens, I am co-leading a clinical trial of new approaches to diagnosing syphilis in HIV-infected MSM that will inform future strategies for controlling these STIs. Third, I am co-leading an international randomized controlled trial in the area of HIV and HSV-2 co-infection, studying whether the anti-herpes medication valacyclovir can slow the rate at which HIV disease progresses. Although there are several potentially harmful ways in which HIV and herpes interact with each other, valacyclovir and related anti-herpes medications are safe and inexpensive. The rationale underlying this trial and my other studies in this area is that these medications could therefore be exploited for clinical benefit by reversing these harmful effects.
Competitiondate
201312
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Tan, Darrell H
Approvedterm
5 ans 0 mois